EQRx, Inc. (EQRX): Price and Financial Metrics

EQRx, Inc. (EQRX): $2.34

0.05 (-2.09%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

D

Add EQRX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#230 of 345

in industry

EQRX Price/Volume Stats

Current price $2.34 52-week high $5.55
Prev. close $2.39 52-week low $1.58
Day low $2.32 Volume 16,554,600
Day high $2.42 Avg. volume 3,297,760
50-day MA $2.25 Dividend yield N/A
200-day MA $2.05 Market Cap 1.14B

EQRX Stock Price Chart Interactive Chart >


EQRx, Inc. (EQRX) Company Bio


EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase I clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.


EQRX Latest News Stream


Event/Time News Detail
Loading, please wait...

EQRX Latest Social Stream


Loading social stream, please wait...

View Full EQRX Social Stream

EQRX Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year -76.52%
5-year N/A
YTD N/A
2023 0.00%
2022 -63.93%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!